SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Prins Bram P.) srt2:(2021)"

Sökning: WFRF:(Prins Bram P.) > (2021)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Gaziano, Liam, et al. (författare)
  • Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19
  • 2021
  • Ingår i: Nature Medicine. - : Springer Nature. - 1078-8956 .- 1546-170X. ; 27:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Large-scale Mendelian randomization and colocalization analyses using gene expression and soluble protein data for 1,263 actionable druggable genes, which encode protein targets for approved drugs or drugs in clinical development, identify IFNAR2 and ACE2 as the most promising therapeutic targets for early management of COVID-19. Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2, P = 1.6 x 10(-6); IFNAR2, P = 9.8 x 10(-11) and IL-10RB, P = 2.3 x 10(-14)) using cis-expression quantitative trait loci genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared expression quantitative trait loci signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.
  •  
2.
  • Klaric, Lucija, et al. (författare)
  • Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19.
  • 2021
  • Ingår i: medRxiv : the preprint server for health sciences. - : Cold Spring Harbor Laboratory. ; , s. 1-28
  • Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
    • Severe COVID-19 is characterised by immunopathology and epithelial injury. Proteomic studies have identified circulating proteins that are biomarkers of severe COVID-19, but cannot distinguish correlation from causation. To address this, we performed Mendelian randomisation (MR) to identify proteins that mediate severe COVID-19. Using protein quantitative trait loci (pQTL) data from the SCALLOP consortium, involving meta-analysis of up to 26,494 individuals, and COVID-19 genome-wide association data from the Host Genetics Initiative, we performed MR for 157 COVID-19 severity protein biomarkers. We identified significant MR results for five proteins: FAS, TNFRSF10A, CCL2, EPHB4 and LGALS9. Further evaluation of these candidates using sensitivity analyses and colocalization testing provided strong evidence to implicate the apoptosis-associated cytokine receptor FAS as a causal mediator of severe COVID-19. This effect was specific to severe disease. Using RNA-seq data from 4,778 individuals, we demonstrate that the pQTL at the FAS locus results from genetically influenced alternate splicing causing skipping of exon 6. We show that the risk allele for very severe COVID-19 increases the proportion of transcripts lacking exon 6, and thereby increases soluble FAS. Soluble FAS acts as a decoy receptor for FAS-ligand, inhibiting apoptosis induced through membrane-bound FAS. In summary, we demonstrate a novel genetic mechanism that contributes to risk of severe of COVID-19, highlighting a pathway that may be a promising therapeutic target.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2
Typ av publikation
annan publikation (1)
tidskriftsartikel (1)
Typ av innehåll
övrigt vetenskapligt/konstnärligt (1)
refereegranskat (1)
Författare/redaktör
Langenberg, Claudia (2)
Zhao, Jing Hua (2)
Gyllensten, Ulf B. (1)
Landén, Mikael, 1966 (1)
Magnusson, Martin (1)
Lind, Lars (1)
visa fler...
Smith, J Gustav (1)
Campbell, Harry (1)
Rönnblom, Lars (1)
Chen, Yan (1)
Wareham, Nicholas J. (1)
Suhre, Karsten (1)
Hansson, Oskar (1)
Johansson, Åsa (1)
Eriksson, Per (1)
Mattsson-Carlgren, N ... (1)
Gaziano, J Michael (1)
Enroth, Stefan, 1976 ... (1)
Wallentin, Lars, 194 ... (1)
Gieger, Christian (1)
Padyukov, Leonid (1)
Folkersen, Lasse (1)
Sun, Yan V. (1)
Allara, Elias (1)
Burgess, Stephen (1)
Walker, Mark (1)
Hedman, Åsa K (1)
Michaëlsson, Karl, 1 ... (1)
Gustafsson, Stefan (1)
Gigante, Bruna (1)
Siegbahn, Agneta, 19 ... (1)
Wilson, James F. (1)
Kooperberg, Charles (1)
Thorand, Barbara (1)
Huffman, Jennifer E (1)
Hayward, Caroline (1)
Prins, Bram P (1)
O'Donnell, Christoph ... (1)
Hwang, Shih-Jen (1)
Casas, Juan P. (1)
Assimes, Themistocle ... (1)
Eriksson, Niclas, 19 ... (1)
Cho, Kelly (1)
Pyarajan, Saiju (1)
Sundstrom, Johan (1)
Esko, Tõnu (1)
Edwards, Todd L (1)
Pereira, Alexandre C ... (1)
Wheeler, Eleanor (1)
Strawbridge, Rona J. (1)
visa färre...
Lärosäte
Uppsala universitet (2)
Göteborgs universitet (1)
Lunds universitet (1)
Karolinska Institutet (1)
Språk
Engelska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2)
År
2021 (2)Ta bort avgränsningen

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy